Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Renal Cell × Protein Subunit Vaccines × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 8 Prostatic Neoplasms 4 Neoplasms 3 Uveal Melanoma 2 Stomach Neoplasms 1 Renal Insufficiency, Chronic 1 Oligodendroglioma 1 Multiple Myeloma 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Glioma 1 Glioblastoma 1 Carcinoma, Renal Cell 1 Bile Duct Neoplasms 1 Astrocytoma 1

Interventions

Nivolumab 129 pembrolizumab 114 Sunitinib 107 Everolimus 63 Bevacizumab 63 Sorafenib 62 cabozantinib 59 pazopanib 55 Ipilimumab 54 Axitinib 49 aldesleukin 47 Magnetic Resonance Spectroscopy 39 Cyclophosphamide 36 Interleukin-2 33 Radiosurgery 32 Interferon-alpha 32 lenvatinib 30 Specimen Handling 26 temsirolimus 23 atezolizumab 23 belzutifan 21 fludarabine phosphate 20 Gemcitabine 20 Radiotherapy 17 Interferon alpha-2 16 Biopsy 16 fludarabine 15 durvalumab 15 avelumab 15 Paclitaxel 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02429440 2017-08-17

UroRCC

University Hospital Tuebingen

Phase 1/2 Unknown

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡